Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation
| Autor: | K.A. Walsh, George A. Davis, Robert J. Kuhn, Don Hayes, Kyle A. Weant, Jeremy D. Flynn |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Volume of distribution
Transplantation medicine.medical_specialty business.industry medicine.medical_treatment Urology Area under the curve medicine.disease Cystic fibrosis Surgery Infectious Diseases Elimination rate constant Pharmacokinetics medicine Tobramycin Lung transplantation business medicine.drug |
| Zdroj: | Transplant Infectious Disease. 13:616-621 |
| ISSN: | 1398-2273 |
| Popis: | K.A. Walsh, G.A. Davis, D. Jr Hayes, R.J. Kuhn, K.A. Weant, J.D. Flynn. Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation. Transpl Infect Dis 2011: 13: 616–621. All rights reserved Study objectives. To compare the pharmacokinetics (PK) of tobramycin in patients with cystic fibrosis (CF) before and after bilateral lung transplantation, in order to evaluate optimal dosing practices post transplant. Design. Retrospective, single-center, chart review study, in which tobramycin concentrations from CF patients were used to calculate PK parameters, including elimination rate constant, half-life, volume of distribution (Vd), area under the curve (AUC), and clearance before and after lung transplantation. Setting. Medical school-affiliated teaching hospital. Patients. Eight patients with CF, who received a bilateral lung transplant from January 1, 2005 through August 1, 2009 (4 males, 4 females; mean age 26.3 years). Interventions. None. Main results. Sixty-nine sets of pre- (n=52) and post transplant (n=17) tobramycin concentrations were available. PK parameters were significantly altered post transplant. Elimination rate constant decreased 38% from 0.26±0.1 to 0.16±0.1 h-1 (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|